The Royal Women's Hospital Melbourne Joins CLEO Ovarian Cancer Trial
Highlights
Leading specialist hospital for women’s health, the Royal Women’s Hospital (the Women's) Melbourne to participate in CLEO’s ovarian cancer trial
The Women's inclusion is designed to broaden patient sampling that will ultimately be used to verify and optimise CLEO’s ovarian cancer blood test
Focus remains on U.S. clinical trial with patient recruitment progressing and program on track to support FDA submission in CY2025
Clinical Trials Advancing
The Royal Women’s Hospital Melbourne Joins CLEO Trial
CLEO has expanded its ovarian cancer Australian trial with the inclusion of the Royal Women’s Hospital as a participating site, with eminent gynaecological oncology specialist, Associate Professor Orla McNally, acting as Principal Investigator. The Women’s is Australia’s leading specialist hospital for women’s health where the partnership aims to:
complement CLEO’s broader trial strategy by increasing the cohort of patient samples;
expand market awareness for CLEO;
verify and optimise CLEO’s ovarian cancer blood test; and
potentially bolster the U.S. trial.
Commenting on the partnership, Associate Professor Orla McNally, Director of Oncology and Dysplasia Service at the Women’s, said:
"Early and accurate detection of ovarian cancer is a critical unmet need. CLEO’s ovarian cancer blood test has the potential to better inform clinical workflows for clinicians to ultimately provide better health outcomes for women.
We are pleased to be working with Cleo Diagnostics on this shared vision.”
Commenting on the trial progress, CLEO Chief Executive, Richard Allman, said:
“The addition of the Royal Women’s Hospital is important to our trials strategy in the context that CLEO is focused on working with leading organisations in the treatment of ovarian cancer.
Our U.S. trials are progressing well which continues to support our plan for FDA submission in 2025. In parallel, we are working across a number of commercial initiatives that will ensure that CLEO’s ovarian cancer blood test is positioned well to be available in our initial markets as soon as possible.”